Bertilimumab ( DrugBank: - )

2 diseases

ID	Disease name (Link within this page)	Number of trials
97	Ulcerative colitis	1
162	Pemphigoid	1

97. Ulcerative colitis

Clinical trials : 2,630 / Drugs : 1,459 - (DrugBank : 265) / Drug target genes : 144 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01671956 (ClinicalTrials.gov)	July 2015	9/8/2012	Evaluation of Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of Bertilimumab in Patients With Active Moderate to Severe Ulcerative Colitis	A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study Designed to Evaluate the Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Profile of Bertilimumab in Patients With Active Moderate to Severe Ulcerative Colitis	Ulcerative Colitis, Active Moderate;Ulcerative Colitis, Active Severe	Biological: Bertilimumab;Biological: Placebo	Immune Pharmaceuticals	NULL	Unknown status	18 Years	70 Years	All	42	Phase 2	Israel

Clinical trials : 90 / Drugs : 122 - (DrugBank : 47) / Drug target genes : 34 - Drug target pathways : 144

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02226146 (ClinicalTrials.gov)	February 2016	27/7/2014	Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid	An Open-Label, Proof of Concept Study Designed to Evaluate the Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Newly Diagnosed, Moderate to Extensive Bullous Pemphigoid	Pemphigoid, Bullous	Biological: Bertilimumab	Immune Pharmaceuticals	NULL	Completed	60 Years	N/A	All	11	Phase 2	United States;Israel